Comprehensive Molecular Characterization of Spinal Cord Gliomas
Frances Chow, Joanne Xiu, Patricia Pittman, Edith Yuan, Tania Vartanians, Phillip Walker, Theodore Nicolaides, Michael Glantz, Ashley
Sumrall, Sonikpreet Aulakh, David Ashley, David Spetzler, Lindsay Hwang, Jason Ye, Eric Chang, James Hu, Frank Attenello, Josh Neman,
David Tran, Gabriel Zada
Clinical management of SCG is currently drawn from experience with intracranial gliomas. Our results identify unique molecular features of SCG suggesting an underlying biology distinct from intracranial gliomas.
In SCG, H3F3A mutations are exclusive to high grade while BRAF fusions are exclusive to low grade; SCG rarely harbor canonical intracranial alterations such as IDH1, EGFR or MGMTme; and SCG have greater penetration of DCs with less penetration of monocytes.
We provide a biological explanation for limited effectiveness of current therapies in SCG with potential implications for chemotherapy, targeted and immunotherapy. Our work underscores the need for investigations dedicated uniquely to SCG